金域医学
(603882)
| 流通市值：139.42亿 | | | 总市值：140.37亿 |
| 流通股本：4.60亿 | | | 总股本：4.63亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,466,504,705.88 | 7,189,544,739.91 | 5,618,852,446.76 | 3,880,906,151.11 |
| 营业收入 | 1,466,504,705.88 | 7,189,544,739.91 | 5,618,852,446.76 | 3,880,906,151.11 |
| 二、营业总成本 | 1,411,296,745.89 | 6,748,751,288.99 | 5,117,588,587.38 | 3,506,295,279.47 |
| 营业成本 | 978,934,517.43 | 4,806,525,640.59 | 3,643,595,996.75 | 2,531,982,051.8 |
| 税金及附加 | 3,260,434.76 | 15,907,999.08 | 11,588,847.08 | 7,851,677 |
| 销售费用 | 213,460,190.85 | 930,618,346.71 | 677,896,671.99 | 453,413,287.27 |
| 管理费用 | 140,587,531.11 | 598,004,111.67 | 483,109,316.58 | 316,142,511.94 |
| 研发费用 | 77,105,975.66 | 400,469,423.29 | 302,366,808.51 | 196,771,885.67 |
| 财务费用 | -2,051,903.92 | -2,774,232.35 | -969,053.53 | 133,865.79 |
| 其中:利息费用 | 4,153,747.33 | 18,428,466.69 | 14,154,937.35 | 9,325,555.66 |
| 其中:利息收入 | 6,851,875.84 | 23,476,697.35 | 16,887,190.64 | 10,607,997.68 |
| 加:公允价值变动收益 | - | -30,798,817.27 | - | - |
| 加:投资收益 | 638,803.17 | -37,083,018.3 | -5,122,643.98 | -1,821,241.47 |
| 资产处置收益 | 2,326,660.53 | 6,364,363.75 | 4,659,777.47 | 3,975,726.92 |
| 资产减值损失(新) | -300,124.76 | -72,623,272.86 | 40,419.96 | 58,054.5 |
| 信用减值损失(新) | -105,894,664.69 | -619,477,916.88 | -420,559,824.32 | -295,987,584.95 |
| 其他收益 | 11,799,078.63 | 39,581,201.81 | 29,929,734.86 | 21,265,390.69 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | -36,222,287.13 | -273,244,008.83 | 110,211,323.37 | 102,101,217.33 |
| 加:营业外收入 | 525,135.48 | 4,587,869.36 | 1,789,837.13 | 1,304,047.16 |
| 减:营业外支出 | 1,617,208.36 | 169,990,378.08 | 16,060,040.36 | 6,527,927.9 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | -37,314,360.01 | -438,646,517.55 | 95,941,120.14 | 96,877,336.59 |
| 减:所得税费用 | -2,588,381.83 | -23,942,816.63 | 12,073,258.49 | 13,615,407.7 |
| 六、净利润 | -34,725,978.18 | -414,703,700.92 | 83,867,861.65 | 83,261,928.89 |
| 持续经营净利润 | -34,725,978.18 | -414,703,700.92 | 83,867,861.65 | 83,261,928.89 |
| 归属于母公司股东的净利润 | -27,785,254.88 | -381,241,138.69 | 93,838,992.07 | 89,650,203.48 |
| 少数股东损益 | -6,940,723.3 | -33,462,562.23 | -9,971,130.42 | -6,388,274.59 |
| (一)基本每股收益 | -0.06 | -0.82 | 0.2 | 0.19 |
| (二)稀释每股收益 | -0.06 | -0.82 | 0.2 | 0.19 |
| 八、其他综合收益 | -1,934,363.99 | 10,627,301.67 | -3,044,204.15 | 3,426,846.19 |
| 归属于母公司股东的其他综合收益 | -1,934,363.99 | 10,627,301.67 | -3,044,204.15 | 3,426,846.19 |
| 九、综合收益总额 | -36,660,342.17 | -404,076,399.25 | 80,823,657.5 | 86,688,775.08 |
| 归属于母公司股东的综合收益总额 | -29,719,618.87 | -370,613,837.02 | 90,794,787.92 | 93,077,049.67 |
| 归属于少数股东的综合收益总额 | -6,940,723.3 | -33,462,562.23 | -9,971,130.42 | -6,388,274.59 |
| 公告日期 | 2025-04-26 | 2025-04-26 | 2024-10-31 | 2024-08-31 |
| 审计意见(境内) | | 标准无保留意见 | | |